Targeted Drug Halts Dangerous Aortic Aneurysm Growth in Preclinical Study

A targeted drug originally investigated for cancer therapy could halt the life-threatening ballooning of the body’s main artery by shutting down specific cellular receptors. Thoracic aortic aneurysm remains a major global health threat that typically requires major surgery once the vessel dilates past a dangerous threshold, because current medicines only offer palliative relief.

To investigate why these vessel walls weaken, a multi-institutional team of European researchers mapped spatial gene activity inside human aortic tissues. Their findings, published in the Journal of Experimental Medicine, reveal that transmembrane proteins called integrins containing the alpha-V subunit act as critical molecular switches driving destructive scarring and tissue degradation.

Mapping the Cellular Drivers of Vessel Weakening

The research team analyzed human tissue samples taken from healthy organ donors alongside specimens from patients undergoing surgical repair for sporadic thoracic aortic aneurysms and syndromic cases linked to Marfan syndrome. Using high-resolution spatial transcriptomics, the investigators mapped thousands of individual gene expressions across different layers of the aortic wall.

The analysis showed that genes encoding alpha-V integrins, collagen remodelling proteins, and signaling molecules associated with transforming growth factor-beta were heavily upregulated in patient tissues compared to healthy controls. These alterations were particularly concentrated at the interface between the middle layer of the aorta and its outer adventitia, specifically within dilated regions where smooth muscle cells had shifted from a normal contractile state to a destructive secretory profile.

Testing Selective Versus Broad Inhibitors in the Lab

Building on these molecular maps, the authors isolated vascular smooth muscle cells from patients and tested two different integrin-blocking drugs to see if they could reverse the pathological changes. One compound, GLPG0187, acts as a broad-spectrum inhibitor blocking multiple integrin types, while the other, Cilengitide, selectively targets specific alpha-V dimers including alpha-V beta-3 and alpha-V beta-5.

Laboratory assays demonstrated that both compounds successfully reduced the release of active transforming growth factor-beta in patient cells without causing cellular toxicity. However, Cilengitide proved notably superior in suppressing both canonical and non-canonical signaling cascades linked to fibrosis. Furthermore, when the team knocked down the gene encoding the alpha-V subunit using lentiviral particles, the pro-fibrotic signaling was similarly blunted, confirming that these specific receptors control the destructive pathways.

Halting Aortic Growth in Preclinical Animal Models

To determine whether these cellular benefits translated into living organisms, the researchers tested both drugs in two distinct mouse models representing genetic Marfan syndrome and chemically induced sporadic aneurysms. Animals treated with vehicle solutions showed progressive, severe dilation of both the ventriculo-aortic annulus and the Valsalva sinus over several weeks.

Echocardiographic monitoring revealed that administering Cilengitide three times a week effectively limited aortic dilation at both anatomical sites in both murine models. By contrast, animals treated with the broad-spectrum inhibitor GLPG0187 showed no statistical difference in aortic diameter compared to untreated diseased controls. Histological staining with Masson trichrome further confirmed that targeted inhibition successfully reduced abnormal collagen deposition and fibrosis within the medial layer of the aortic wall.

Potential Pathways Toward Clinical Translation

The study authors emphasize that because Cilengitide has already undergone extensive human testing and pharmacokinetic profiling in oncology clinical trials, its potential repurposing for cardiovascular conditions could move forward efficiently. While broader systemic blockade of transforming growth factor-beta often causes severe side effects because of its diverse physiological roles throughout the body, targeting specific integrin receptors offers a way to selectively suppress local fibrosis.

Future clinical investigations will need to evaluate whether Cilengitide should be administered as a standalone therapy or combined with standard medications such as beta-blockers or angiotensin receptor blockers. If successful in upcoming human trials, this precision pharmacological approach could finally provide an etiological treatment option for patients facing the constant risk of aortic dissection and rupture.

The research was published in The Journal of experimental medicine on December 7, 2026.